These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 12093306)

  • 21. Pharmacovigilance activities in Nepal.
    Palaian S; Mohamed Ibrahim MI; Mishra P; Alam K; Shankar PR; Thapa BB
    Drug Saf; 2010 Oct; 33(10):889-90. PubMed ID: 20812773
    [No Abstract]   [Full Text] [Related]  

  • 22. EUROmediCAT: Safety of Medication Use in Pregnancy.
    Pharmacoepidemiol Drug Saf; 2015 Oct; 24 Suppl 2():1-2. PubMed ID: 26395592
    [No Abstract]   [Full Text] [Related]  

  • 23. What do stakeholders think about pharmacovigilance?
    Edwards IR; Graedon T
    Drug Saf; 2010 Aug; 33(8):619-21. PubMed ID: 20635819
    [No Abstract]   [Full Text] [Related]  

  • 24. Substandard drugs: a potential crisis for public health.
    Johnston A; Holt DW
    Br J Clin Pharmacol; 2014 Aug; 78(2):218-43. PubMed ID: 24286459
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping of the WHO-ART terminology on Snomed CT to improve grouping of related adverse drug reactions.
    Alecu I; Bousquet C; Mougin F; Jaulent MC
    Stud Health Technol Inform; 2006; 124():833-8. PubMed ID: 17108616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug quality as a cause of drug related problems].
    Sotoca-Momblona JM; Sisó-Almirall A
    Med Clin (Barc); 2006 Apr; 126(15):599. PubMed ID: 16756929
    [No Abstract]   [Full Text] [Related]  

  • 27. International monitoring for adverse drug reactions of long latency.
    Fletcher AP; Griffin JP
    Adverse Drug React Toxicol Rev; 1991; 10(4):209-30. PubMed ID: 1793771
    [No Abstract]   [Full Text] [Related]  

  • 28. [International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group].
    Royer RJ; Benichou C
    Therapie; 1991; 46(3):173-8. PubMed ID: 1792648
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug product characteristics that foster drug-use-system errors.
    Cohen MR
    Am J Health Syst Pharm; 1995 Feb; 52(4):395-9. PubMed ID: 7757867
    [No Abstract]   [Full Text] [Related]  

  • 30. How should we react to adverse drug reactions?
    Ferner RE; Beard K
    Postgrad Med J; 2011 Feb; 87(1024):81-2. PubMed ID: 21303818
    [No Abstract]   [Full Text] [Related]  

  • 31. Health risks of counterfeit pharmaceuticals.
    ten Ham M
    Drug Saf; 2003; 26(14):991-7. PubMed ID: 14583061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Strategy for surveillance of adverse drug events.
    Bright RA
    Food Drug Law J; 2007; 62(3):605-16. PubMed ID: 17915403
    [No Abstract]   [Full Text] [Related]  

  • 33. Does public perception bias lead to more frequent reporting of adverse events: branded vs generic drugs.
    Qian J; Mishuk AU; Hansen RA
    Expert Opin Drug Saf; 2018 Aug; 17(8):753-756. PubMed ID: 30052091
    [No Abstract]   [Full Text] [Related]  

  • 34. [Safety of medicinal products and reporting of adverse drug reactions].
    Skibicka I; Maciejczyk A
    Neurol Neurochir Pol; 2004; 38(6):503-10. PubMed ID: 15654675
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multinational medicines--ensuring drug quality in an era of global manufacturing.
    Okie S
    N Engl J Med; 2009 Aug; 361(8):737-40. PubMed ID: 19692686
    [No Abstract]   [Full Text] [Related]  

  • 36. Outlier removal to uncover patterns in adverse drug reaction surveillance - a simple unmasking strategy.
    Juhlin K; Ye X; Star K; Norén GN
    Pharmacoepidemiol Drug Saf; 2013 Oct; 22(10):1119-29. PubMed ID: 23832706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs.
    Bohn J; Kortepeter C; Muñoz M; Simms K; Montenegro S; Dal Pan G
    Clin Pharmacol Ther; 2015 May; 97(5):508-17. PubMed ID: 25670505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. National differences in reporting 'pneumonia' and 'pneumonia interstitial': an analysis of the WHO International Drug Monitoring Database on 15 drugs in nine countries for seven pulmonary conditions.
    Koo LC; Clark JA; Quesenberry CP; Higenbottam T; Nyberg F; Wolf MK; Steinberg MH; Forsythe BH
    Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):775-87. PubMed ID: 15654720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Updating the French method for the causality assessment of adverse drug reactions.
    Arimone Y; Bidault I; Dutertre JP; Gérardin M; Guy C; Haramburu F; Hillaire-Buys D; Meglio C; Penfornis C; Théophile H; Valnet-Rabier MB;
    Therapie; 2013; 68(2):69-76. PubMed ID: 23773347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Competing in drug safety.
    Edwards R
    Lancet; 1993 Sep; 342(8872):631-2. PubMed ID: 8103142
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.